SARS-CoV-2 screening in pediatric cancer patients before hospitalization for chemotherapy infusionArticle Published on 2022-04-012023-07-08 Journal: Archivos argentinos de pediatría [Category] COVID19(2023년), [키워드] Chemotherapy COVID-19 Mass screening Neoplasms [DOI] 10.5546/aap.2022.eng.118
JAK inhibitors and COVID-19JAK 억제제 및 COVID-19Review Published on 2022-04-012022-09-11 Journal: Journal for immunotherapy of cancer [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] activated added Antiviral antiviral molecules Autoimmunity Baricitinib benefit clinical experience clinical trials coded concerning contributing to COVID-19 COVID-19 treatment cut-off cytokine Cytokine storm Cytokines differentiation Effect Effects Evolution family Graft hematologic hematologic neoplasms Human genome immune regulation immune response Immunosuppression immunosuppressive effect immunosuppressive effects indicated induce inhibited innate immune response interferons involved issue Jak JAK inhibitor jak inhibitors JAK1 JAK2 JAK3 JAKi janus Janus kinase kinases Meta-analysis moment Neoplasms nezulcitinib outcome pathogenic pathway Pathways patients treated patients with COVID-19 Phase 3 trials proliferation randomized clinical trial RCT reaction receptor reduce mortality rheumatic disease Rheumatic diseases risk reduction ruxolitinib SARS-COV-2 infection severe COVID-19 Side effect Signaling Significant Standard of care subsequent suggested survival the SARS-CoV-2 the WHO Therapies therapies, investigational. Tofacitinib transmembrane Treatment trials TYK2 Type I IFN type I interferons Viral viral replication virus clearance [DOI] 10.1136/jitc-2021-002838 PMC 바로가기 [Article Type] Review
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination settingClinical Trial Published on 2022-03-102022-10-05 Journal: Blood [Category] SARS, 임상, [키워드] 1:1 95% CI Active disease Analysis controls COVID-19 COVID-19 immunity COVID-19 infection COVID-19 vaccine COVID-19-related death doses Effectiveness ENhance evaluated hematological Hospitalization humoral immune system Immunity increased risk Infection mRNA BNT162b2 vaccine neoplasm Neoplasms observation outcome Patient patient population patients patients receiving treatment polymerase chain receiving recipient risk severe COVID-19 symptomatic therapy Treatment vaccinated individual vaccination vaccine dose [DOI] 10.1182/blood.2021013768 PMC 바로가기 [Article Type] Clinical Trial
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHAClinical Trial Published on 2022-03-102022-10-05 Journal: Blood [Category] SARS, 임상, [키워드] approach Blood booster Breakthrough infection Cancer Clinical efficacy controls COVID-19 COVID-19 disease death EPICOVIDEHA Guidance healthy hematologic Hematologic malignancy hematological higher risk Hospitalization incidence lymphoid malignancies mRNA vaccination Neoplasms observation outcome paper Patient public health Serologic response therapy vaccination [DOI] 10.1182/blood.2021014124 PMC 바로가기 [Article Type] Clinical Trial
Precautionary measures before tailoring and commencing a tele-supervised home-based exercise oncology program for older patients with cancer and post-treatment cancer survivors in the COVID-19 eraShort communication Published on 2022-03-012022-10-05 Journal: Journal of geriatric oncology [Category] SARS, 치료법, [키워드] Cancer Clinical oncology COVID-19 elderly exercises measure Neoplasms older patient oncology survivor telehealth [DOI] 10.1016/j.jgo.2021.08.001 [Article Type] Short communication
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trialClinical Trial Published on 2022-03-012022-10-05 Journal: Vaccine [Category] SARS, 임상, [키워드] AEs baseline BNT162b2 BNT162b2 mRNA BNT162b2 vaccine Cancer clinical clinical trials COVID-19 COVID-19 pandemic COVID-19 vaccine death Efficacy Efficacy and safety excluded fatigue Follow-up follow-up time high risk Hospitalization immunosuppressive incidence rate individual Infection Injection-site pain malignancy Melanoma MOST neoplasm Neoplasms observer-blinded outcomes participant Participants Phase 3 Placebo placebo recipient placebo-controlled Prostate Pyrexia Randomized randomized clinical trial reactogenicity event receiving reported Safe Safety subgroup analysis therapy Trial unblinding Vaccine were excluded [DOI] 10.1016/j.vaccine.2021.12.046 PMC 바로가기 [Article Type] Clinical Trial
Variation in colon cancer survival for patients living and receiving care in London, 2006–2013: does where you live matter?Original Research Published on 2022-02-162022-10-29 Journal: Journal of epidemiology and community health [Category] Coronavirus, COVID19(2023년), MERS, SARS, [키워드] analysed applied Bayesian Cancer Care clinical clinician Colon cancer COVID-19 pandemic described diagnosed Diagnosis diagnostic tests England Evidence examined expected Geography group Health policy hierarchical structure highlight hospital hospitals IMPROVE inequalities investigated London microcosm mimicking multilevel modelling Neoplasms pathway Patient proportion receiving Result secondary care suggested survival Variation [DOI] 10.1136/jech-2021-217043 PMC 바로가기 [Article Type] Original Research
Unemployment and cancer screening: Baseline estimates to inform health care delivery in the context of COVID-19 economic distressArticle Published on 2022-02-152023-06-19 Journal: Cancer [Category] MERS, [키워드] cancer detection Cancer screening Coronavirus disease 2019 (COVID-19) Disparities Economy Health Insurance Neoplasms race/ethnicity unemployment [DOI] 10.1002/cncr.33966 PMC 바로가기
Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysisMeta-Analysis Published on 2022-02-012023-07-06 Journal: Cancer immunology, immunotherapy : CII [Category] COVID19(2023년), [키워드] Checkpoint inhibitor COVID-19 Neoplasms Prognosis Programmed cell death 1 receptor. [DOI] 10.1007/s00262-021-02990-9 PMC 바로가기 [Article Type] Meta-Analysis
The impact of face shields on the quality of gastrointestinal endoscopy during the COVID-19 pandemicResearch Published on 2022-01-292022-10-27 Journal: BMC Gastroenterology [Category] COVID-19, [키워드] Adenomatous polyps ADRS affected calculated Colonic polyps Colonoscopy Complete Coronavirus disease 2019 COVID-19 COVID-19 pandemic detection rate determine disposable gloves endoscopy ESD examined Face shield FIVE global pandemic groups healthcare worker high risk Isolation Mask medical record Neoplasms not affect pandemic Patient PDR Personal protective equipment PPE Prevent reported Result serrated statistically significant statistically significant difference Surveillance university wearing [DOI] 10.1186/s12876-022-02114-2 PMC 바로가기 [Article Type] Research